[HTML][HTML] Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential
X Wang, X Yang, X Yuan, W Wang, Y Wang - Experimental Hematology & …, 2022 - Springer
Chimeric antigen receptor (CAR)-engineered T (CAR-T) cells have obtained prominent
achievement in the clinical immunotherapy of hematological malignant tumors, leading to a …
achievement in the clinical immunotherapy of hematological malignant tumors, leading to a …
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential
X Wang, X Yang, X Yuan… - Experimental …, 2022 - pubmed.ncbi.nlm.nih.gov
Chimeric antigen receptor (CAR)-engineered T (CAR-T) cells have obtained prominent
achievement in the clinical immunotherapy of hematological malignant tumors, leading to a …
achievement in the clinical immunotherapy of hematological malignant tumors, leading to a …
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential
X Wang, X Yang, X Yuan, W Wang… - Experimental …, 2022 - search.proquest.com
Chimeric antigen receptor (CAR)-engineered T (CAR-T) cells have obtained prominent
achievement in the clinical immunotherapy of hematological malignant tumors, leading to a …
achievement in the clinical immunotherapy of hematological malignant tumors, leading to a …
[HTML][HTML] Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential
X Wang, X Yang, X Yuan… - Experimental …, 2022 - ehoonline.biomedcentral.com
Chimeric antigen receptor (CAR)-engineered T (CAR-T) cells have obtained prominent
achievement in the clinical immunotherapy of hematological malignant tumors, leading to a …
achievement in the clinical immunotherapy of hematological malignant tumors, leading to a …
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential
X Wang, X Yang, X Yuan, W Wang… - … Hematology & Oncology, 2022 - europepmc.org
Chimeric antigen receptor (CAR)-engineered T (CAR-T) cells have obtained prominent
achievement in the clinical immunotherapy of hematological malignant tumors, leading to a …
achievement in the clinical immunotherapy of hematological malignant tumors, leading to a …
[HTML][HTML] Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential
X Wang, X Yang, X Yuan, W Wang… - … Hematology & Oncology, 2022 - ncbi.nlm.nih.gov
Chimeric antigen receptor (CAR)-engineered T (CAR-T) cells have obtained prominent
achievement in the clinical immunotherapy of hematological malignant tumors, leading to a …
achievement in the clinical immunotherapy of hematological malignant tumors, leading to a …
[PDF][PDF] Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential
X Wang, X Yang, X Yuan, W Wang, Y Wang - 2022 - ehoonline.biomedcentral.com
Chimeric antigen receptor (CAR)-engineered T (CAR-T) cells have obtained prominent
achievement in the clinical immunotherapy of hematological malignant tumors, leading to a …
achievement in the clinical immunotherapy of hematological malignant tumors, leading to a …
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential.
X Wang, X Yang, X Yuan, W Wang… - … Hematology & Oncology, 2022 - europepmc.org
Chimeric antigen receptor (CAR)-engineered T (CAR-T) cells have obtained prominent
achievement in the clinical immunotherapy of hematological malignant tumors, leading to a …
achievement in the clinical immunotherapy of hematological malignant tumors, leading to a …